Premium
Atheroprotective effects of conjugated linoleic acid
Author(s) -
Bruen Robyn,
Fitzsimons Stephen,
Belton Orina
Publication year - 2017
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/bcp.12948
Subject(s) - conjugated linoleic acid , linoleic acid , macrophage , chemistry , monocyte , biochemistry , medicine , biology , endocrinology , fatty acid , in vitro
Atherosclerosis, the underlying cause of heart attack and strokes, is a progressive dyslipidaemic and inflammatory disease where monocyte‐derived macrophage cells play a pivotal role. Although most of the mechanisms that contribute to the progression of atherosclerosis have been identified, there is limited information on those governing regression. Conjugated linoleic acid (CLA) is a generic term denoting a group of naturally occurring isomers of linoleic acid (18:2, n6) that differ in the position or geometry (i.e. cis or trans ) of their double bonds. The most predominant isomers in ruminant fats are cis ‐9, trans ‐11 CLA (c9,t11‐CLA), which accounts for more than 80% of CLA isomers in dairy products and trans ‐10, cis ‐12 CLA (t10,c12‐CLA). Dietary administration of a blend of the two most abundant isomers of CLA has been shown to inhibit the progression and induce the regression of pre‐established atherosclerosis. Studies investigating the mechanisms involved in CLA‐induced atheroprotective effects are continually emerging. The purpose of this review is to discuss comprehensively the effects of CLA on monocyte/macrophage function in atherosclerosis and to identify possible mechanisms through which CLA mediates its atheroprotective effects.